Healthcare 3 March 2026 - 31 March 2026

Blackstone Raises Record $6.3 Billion Life Sciences Fund to Back Pharma and Medtech Programs
···

Blackstone Raises Record $6.3 Billion Life Sciences Fund to Back Pharma and Medtech Programs

Blackstone wrapped up its largest life sciences fund to date, closing at $6.3 billion. It’s calling the fund—the Blackstone Life Sciences VI—the largest private vehicle dedicated to the sector. According to the company, the capital will be deployed to fuel new pharma and medtech projects. Timing isn’t trivial here. On Tuesday, Biogen put $5.6 billion on the table for Apellis Pharmaceuticals, while Eli Lilly moved to scoop up Centessa in a deal that could reach $7.8 billion. Both are betting big on future drugs as patent cliffs get nearer. This trend is making room for specialist funds to step in and finance those costly, late-stage development phases before launch.
March 31, 2026
4DMedical Ltd Wins EU CE Mark, Raises A$83 Million as Mayo Clinic Deal Boosts CT:VQ Push
···

4DMedical Ltd Wins EU CE Mark, Raises A$83 Million as Mayo Clinic Deal Boosts CT:VQ Push

4DMedical disclosed in a Friday filing that its CT:VQ technology secured European Union CE mark certification. The Australian medtech also said it had raised A$83 million from institutional investors, a boost to fund its European ambitions. Shares ended the day at A$6.28, having hit A$7.55 earlier in the session. The timing comes into play as 4DMedical looks to build on recent U.S. hospital contracts and push for wider commercial uptake. According to the company, CT:VQ assesses how air and blood flow throughout the lungs using regular non-contrast CT scans—skipping the radiotracers needed for classic nuclear V/Q imaging.
March 29, 2026
GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects
···

GSK Stock Rises as EMA Review of Bepirovirsen Lifts 2026 Approval Prospects

GSK shares picked up on Friday, trading at roughly 2,056 pence by 13:47 in London, a 0.54% gain, after the company announced the European Medicines Agency is set to review bepirovirsen, its investigational chronic hepatitis B therapy. The filing is significant—GSK has highlighted bepirovirsen as one of just two major product approvals it’s counting on for 2026, a year when the company has projected revenue growth will drop to between 3% and 5%, after hitting 7% in 2025. For CEO Luke Miels, the drug is part of the slate of new therapies he needs to offset looming patent expiries in GSK’s HIV portfolio.
March 27, 2026
GSK Stock Price Today: Shares Jump on Japan Orphan-Drug Nod
···

GSK Stock Price Today: Shares Jump on Japan Orphan-Drug Nod

GSK climbed 3.2% to 2,039.5 pence in London as of 1208 GMT on Wednesday. The move came after Japan gave orphan-drug status to the company's experimental lung-cancer drug risvutatug rezetecan, and a fresh filing confirmed GSK was continuing its stock buybacks. This shift carries weight for GSK, which has already signaled to investors it’s bracing for slower sales growth this year. That puts launches and pipeline successes front and center as patent cliffs approach for its leading HIV medicines. Back in February, the company guided for 2026 revenue to increase 3% to 5%—currency impacts aside—and reiterated its target of topping £40 billion in annual sales by 2031. New CEO Luke Miels described the task ahead as needing to “accelerate what
March 25, 2026
Sigma Healthcare Share Price Jumps 4.5% After Jefferies Upgrade Revives Chemist Warehouse Focus
····

Sigma Healthcare Share Price Jumps 4.5% After Jefferies Upgrade Revives Chemist Warehouse Focus

Sigma Healthcare jumped 4.5% to A$2.78 on March 20, landing the Chemist Warehouse owner near the top of the blue-chip board. Jefferies bumped its rating to buy from hold, tagging a A$3.05 target price. This one stood out—trading volume surged to 103 million shares, a sharp leap from the 10.9 million to 19.5 million range seen over the previous four sessions. Even with Friday’s bounce, the stock remained roughly 5.4% lower for the year.
March 22, 2026
GSK Stock Price Slips as Buyback Continues and Linerixibat Decision Looms
····

GSK Stock Price Slips as Buyback Continues and Linerixibat Decision Looms

GSK shares dropped 0.7% to 2,051 pence by 0946 GMT on Thursday, after the company announced fresh buybacks. London stocks were feeling the heat from resurging oil-fueled inflation jitters. According to a filing, GSK repurchased 513,409 shares on March 11, paying an average of 2,061.69 pence each. The new filing is a key move for GSK, which is working to prove it can keep delivering cash to shareholders even as CEO Luke Miels revamps the company’s drug pipeline. Shares surged to a multi-decade peak after February’s earnings, when Miels reaffirmed GSK’s long-term sales outlook. He also flagged the need for smaller acquisitions and quicker drug development if the company wants to offset looming patent expiries on its blockbuster HIV treatments
March 12, 2026
CSL Limited Breaks Ground on $1.5 Billion Illinois Plant as Turnaround Pressure Builds
···

CSL Limited Breaks Ground on $1.5 Billion Illinois Plant as Turnaround Pressure Builds

MELBOURNE, March 11, 2026, 09:36 AEDT CSL Limited has kicked off construction on a $1.5 billion expansion at its Kankakee, Illinois, plant, sharpening its focus on the business segment leaders hope will fuel future growth. The project targets increased production of plasma-derived therapies—drugs sourced from proteins in donated human plasma—and is set to come online by 2031, bringing at least 300 new pharma jobs with it.
March 11, 2026
Pro Medicus Ltd locks in A$40 million U.S. renewals as MedStar adds heart-imaging tools
····

Pro Medicus Ltd locks in A$40 million U.S. renewals as MedStar adds heart-imaging tools

Pro Medicus announced Monday its U.S. arm locked in two renewed imaging software deals totaling at least A$40 million. The bigger slice, an A$31 million extension with MedStar Health, will bring new heart-imaging capabilities. Another A$9 million contract covers a renewal with Zwanger-Pesiri, a radiology group on Long Island. Both renewals locked in higher per-transaction fees, and there’s still upside if scan volumes climb. They also push Pro Medicus further into the U.S. market, while the MedStar deal now stretches into cardiology.
March 11, 2026
JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead
···

JPMorgan Chase Faces Fresh Legal Pressure as Employee Drug-Cost Suit Moves Ahead

A federal judge in Manhattan has let key claims move forward in a proposed class action that targets JPMorgan Chase over alleged mismanagement of its health and prescription benefits plan. According to the lawsuit, employees in the country’s biggest bank say they were charged too much for both drugs and premiums. This ruling drops into the middle of an escalating dispute over how large companies oversee drug-plan vendors. It comes on the heels of the U.S. Supreme Court’s April 2025 Cornell decision, which lowered the bar for workers to keep certain ERISA cases alive early on. ERISA is the federal law covering workplace benefit plans.
March 10, 2026
UnitedHealth Group Faces Fresh Medicare Advantage Pressure Ahead of Barclays Investor Event
····

UnitedHealth Group Faces Fresh Medicare Advantage Pressure Ahead of Barclays Investor Event

WASHINGTON, March 10, 2026, 10:41 EDT. UnitedHealth Group Incorporated faces renewed scrutiny as it heads into a scheduled investor event on Tuesday, following a Wall Street Journal report that a congressional committee determined seniors shelled out roughly 10% more for Medicare Part B premiums last year. The increase stems from alleged overpayments to private Medicare Advantage plans, according to the findings. Later Tuesday, the insurer is slated to outline its strategy and go over recent performance at a Barclays healthcare conference, as detailed in a March 9 filing.
March 10, 2026
Amazon Launches Connect Health, Pushing AWS Deeper Into Healthcare AI
···

Amazon Launches Connect Health, Pushing AWS Deeper Into Healthcare AI

Seattle, March 6, 2026, 4:32 AM UTC-08:00 Amazon.com’s cloud arm rolled out a new AI tool for healthcare on Thursday, stepping further into a sector where hospitals are eager to automate phone calls, paperwork, and billing. The new offering, Amazon Connect Health, taps what AWS is calling agentic AI — software built to handle tasks with minimal human input — and integrates directly into electronic health records, or EHRs. That lets it check patient details, handle appointment scheduling, draft notes, and produce billing codes, all within the digital systems clinicians already use.
March 6, 2026
CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares
····

CSL Limited Wins Canada Pandemic Vaccine Contract as Buyback Tops 4 Million Shares

CSL Ltd's vaccine business, Seqirus, has locked in a Canadian government contract to deliver up to 15 million pandemic influenza vaccine doses from its Victoria site if a flu pandemic is declared by the World Health Organization. This marks the first supply deal for CSL’s new Tullamarine facility outside the Asia-Pacific region, the company noted. Timing counts here. CSL badly needed some positive news, coming off an eight-year share price low last month after the biotech logged an 81% plunge in half-year profit and unexpectedly swapped out its chief executive. For Seqirus, the deal lands as a rare export win not long after CSL abandoned plans to spin off the vaccines unit, following a decline in U.S. flu vaccine uptake.
March 6, 2026
Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap
···

Eli Lilly’s $449 Zepbound play: new “Employer Connect” targets workplace coverage gap

Eli Lilly rolled out its “Employer Connect” platform Thursday, aiming to give U.S. employers a new way to expand access to the weight-loss drug Zepbound. The Zepbound KwikPen will be available through network pharmacies for $449—same price, all doses. Shares of Lilly slipped roughly 2% in late New York trading. “By enabling coverage outside traditional benefit designs, we lower barriers to treatment,” said Kevin Hern, senior VP at Lilly. Employers are under pressure to handle surging demand for GLP-1 obesity drugs—these treatments work by mimicking gut hormones to reduce hunger and stabilize blood sugar—while also keeping benefit expenses in check. Speaking with Fierce Healthcare, Hern said the goal is to “ease tensions” that have sidelined some employers, though workers’ final
March 6, 2026
Amazon debuts ‘agentic AI’ healthcare tool to cut clinic call times and paperwork
···

Amazon debuts ‘agentic AI’ healthcare tool to cut clinic call times and paperwork

Seattle — It’s 1:23 p.m. PST on March 5, 2026. Amazon.com, Inc. on Thursday rolled out Amazon Connect Health, a new AI-powered platform from its cloud division, Amazon Web Services. The product is designed to handle repetitive administrative tasks, like appointment scheduling and billing. AWS says it integrates directly with hospitals’ and clinics’ electronic health records, funneling more complex situations to human staff.
March 5, 2026
Medline backers cash out in $3.1 billion share sale priced at $41
···

Medline backers cash out in $3.1 billion share sale priced at $41

Shareholders of Medline Inc. have set the price on a 75 million-share secondary offering at $41 apiece, valuing the transaction near $3.1 billion. The move hands Medline’s private equity owners another path to exit. https://newsroom.medline.com/releases/pricing-secondary-offering-class-a-common-stock/ A secondary offering involves selling shares already in circulation—no new funds head to the company. Medline clarified: it’s not putting any of its own stock up for sale and won’t pocket any cash from the deal. Even so, investors keep an eye on these moves, since more shares in the market can bump up the float and weigh on the stock in the short run. https://newsroom.medline.com/releases/secondary-offering-class-a-common-stock/
March 5, 2026
Stevanato Group (STVN) shares jump after 2026 outlook leans on GLP-1 drug packaging
····

Stevanato Group (STVN) shares jump after 2026 outlook leans on GLP-1 drug packaging

Stevanato Group S.p.A. rolled out its inaugural 2026 guidance Wednesday, eyeing revenue between €1.26 billion and €1.29 billion and projecting adjusted EBITDA in the €331.8 million to €346.9 million range. That figure strips out interest, taxes, depreciation, amortization and certain other items. The Italian drug-packaging firm noted GLP-1 products—used for diabetes and weight management—accounted for roughly 19% to 20% of 2025 revenue, which climbed 7% to €1.186 billion. Guidance is under scrutiny these days, as packaging is now a sticking point for injectable drugs—think vaccines or the current obesity and diabetes therapies. Drugmakers are pushing for more ready-to-use parts to keep filling lines running and sidestep production halts.
March 5, 2026
Bradesco sets March 31 vote on Bradseg spin-off in Bradsaúde healthcare push
···

Bradesco sets March 31 vote on Bradseg spin-off in Bradsaúde healthcare push

Banco Bradesco put forward a distance voting ballot for an extraordinary shareholders' meeting set for March 31, aiming to get the green light on a partial spin-off of its unit Bradseg Participações, according to a U.S. filing. This vote is key. Bradesco needs approval to fold its healthcare assets into Odontoprev, reshaping the listed firm into a holding company. For Bradesco, it’s a straightforward, high-profile move—one that steers clear of altering its own share capital.
March 4, 2026
1 2 3 4 5 6